

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/510,126	10/04/2004	Gerardo Perez-Camargo	115808-511	6573	
29157 K&L Gates LI	7590 06/05/200 P	9	EXAMINER		
P.O. Box 1135	-		BARHAM, E	BARHAM, BETHANY P	
CHICAGO, IL	. 60690		ART UNIT	PAPER NUMBER	
			1615		
			NOTIFICATION DATE	DELIVERY MODE	
			06/05/2009	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

chicago.patents@klgates.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/510,126	PEREZ-CAMARGO ET AL.	
Examiner	Art Unit	
BETHANY BARHAM	1615	

	BETHANY BARHAM	1615						
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress					
THE REPLY FILED 21 May 2009 FAILS TO PLACE THIS APP	THE REPLY FILED 21 May 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	☑ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places i application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 4.1.31; or (3) a Reque for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time							
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is Examiner Note: If box 1 is checked, check either box (a) or MONTHS OF THE FINAL REJECTION. See MPEP 706.07(dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.					
Extensions of time may be obtained under 37 CFR 1.136(a). The data have been filed is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	ension and the corresponding amount of shortened statutory period for reply origing than three months after the mailing date	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as					
The Notice of Appeal was filed on . A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exten Notice of Appeal has been filed, any reply must be filed w AMENDMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the						
	nsideration and/or search (see NOT w);	E below);						
appeal; and/or (d) They present additional claims without canceling a one of the control of the canceling and NOTE: (See 37 CFR 1.116 and 41.33(a)).								
4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be all non-allowable claim(s).								
7. \(\subseteq \text{ for purposes of appeal, the proposed amendment(s): a) } \) how the new or amended claims would be rejected is prov. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: \[\subseteq \text{ (Claim(s) allowed:} \]		be entered and an e	xplanation of					
Claim(s) objected to: Claim(s) rejected: 48-53.55 and 58-60. Claim(s) withdrawn from consideration: 38-47 and 61-71.								
AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).								
The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary.	vercome <u>all</u> rejections under appear and was not earlier presented. Se	and/or appellant fail: e 37 CFR 41.33(d)(1	s to provide a).					
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.					
The request for reconsideration has been considered bu <u>See Continuation Sheet</u>		condition for allowan	ce because:					
12. Note the attached Information Disclosure Statement(s). (13. Other:	PTO/SB/08) Paper No(s).							

Continuation of 11. does NOT place the application in condition for allowance because: the proposed amendment raises new issues that would require further consideration and/or search and potentially new matter and will therefore NOT be entered. Applicant states that the proposed amendment is supported at pg. 6, lines 28-29, however the proposed amendment relates to a 'first' and 'second' pancreatic funtion promoter, wherein the first is a pancreatic extract and the second is a gut pH modifier. The instant specification states (pg. 6, lines 22-29) "a pancreatic function promoter" implying a single pancreatic function promoter and secondly teaches "comprises a lipase, a gut pH modifier or a pancreatic extract" wherein "or" teaches the alternative, not combination or mixtures thereof and as such is new matter. As such the claims 48-53, 55 and 58-60 remain rejected over anticipatory 102: '252, '226, '367 or '667 alone, or obviousness 103: '999 in view of '063 or '206; or '719 in view of '063 or '206, which teach various compositions comprising combinations of fish oil and pancreatin/lipase with vitamins/minerals/amino acids/gluthathione promoters and whey proteins.

/MP WOODWARD/ Supervisory Patent Examiner, Art Unit 1615